Rx only · Injection · Intravenous

Eptifibatide

3 ACTIVE SUPPLIERS — US

openFDA · updated weekly

US8 NDCs
3 active makers

UKComing
soon

CAComing
soon

AUComing
soon

EUComing
soon

RxCUI (US)75635

US makers3 labelers

Packages8

DEA / ScheduleNone

Medicaid dispensing volume

No Medicaid utilization on record for this drug concept yet. Quarterly volume (CMS State Drug Utilization Data) loads with the utilization ETL.

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

Labeler	Type	Packages	Status
Slate Run Pharmaceuticals, LLC	unknown	4	SUPPLYING
Eugia US LLC	unknown	3	SUPPLYING
Baxter Healthcare Corporation	unknown	1	SUPPLYING

Shortages, recalls, and registration changes attached to this drug concept.

Feb 12, 2026
RECALLRecall (Class III): Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous …
Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion. — Recalling firm: Slate Run Pharmaceuticals — Nationwide within the USA.
May 22, 2024
RECALLRecall (Class III): Eptifibatide injection 20mg/10mL (2mg/mL), 10mL Single-Dose Vial, Rx only, Mfd. In India for: AuroMedics Pharma, LLC, E…
Failed Impurities/Degradation Specifications: failed related substance identified as Eptifibatide dimer. — Recalling firm: Eugia US LLC — USA nationwide.